» Articles » PMID: 10874312

Mutational Analysis of BRCA1 and BRCA2 Genes in Chinese Ovarian Cancer Identifies 6 Novel Germline Mutations

Overview
Journal Hum Mutat
Specialty Genetics
Date 2000 Jun 30
PMID 10874312
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Germline mutations in the BRCA1 and BRCA2 genes predispose women to breast and ovarian cancer. An incidence of 5% and 3.3% respectively has been reported of BRCA1 and BRCA2 mutations in women with ovarian cancer unselected for family history. The contribution of BRCA1 and BRCA2 mutations to ovarian cancer in Chinese women is unknown. A total of 60 samples of ovarian cancer diagnosed in Chinese unselected for age or family history were analyzed for BRCA mutations using the protein truncation test. The entire coding exon of BRCA1 of 53 cases and that of exon 11 of BRCA2 of 43 cases were successfully screened. Six germline (11.3%) mutations (633C>T, 1080delT, 1129delA, 2371-2372delTG, 3976-3979delGTGA, and IVS 22+7 A>G) were detected in BRCA1. One germline mutation (3337C>T) (2.1%) was detected in BRCA2. None of these seven cases were associated with strong family history of breast and/or ovarian cancer. Five out of our six BRCA1 mutations and the one BRCA2 mutation identified are novel. Our 11.3% incidence of BRCA1 mutations in ovarian cancer found amongst Chinese with insignificant family history is apparently higher than that previously reported in other populations. It suggests that BRCA1 mutation may play a significant role in the development of sporadic ovarian cancer in Chinese women.

Citing Articles

Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer.

Li L, Chen F, Lin A, Wang D, Shi Y, Chen G Comput Math Methods Med. 2021; 2021:4854282.

PMID: 34721658 PMC: 8554521. DOI: 10.1155/2021/4854282.


A Case Report of Germline Compound Heterozygous Mutations in the Gene of an Ovarian and Breast Cancer Patient.

Kwong A, Ho C, Shin V, Au C, Chan T, Ma E Int J Mol Sci. 2021; 22(2).

PMID: 33477375 PMC: 7830606. DOI: 10.3390/ijms22020889.


Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.

Ashour M, Ezzat Shafik H Cancer Manag Res. 2019; 11:6275-6284.

PMID: 31372034 PMC: 6626894. DOI: 10.2147/CMAR.S206817.


BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.

Cardoso F, Goncalves S, Mele P, Liria N, Sganga L, Diaz Perez I Hum Genomics. 2018; 12(1):39.

PMID: 30103829 PMC: 6090818. DOI: 10.1186/s40246-018-0171-5.


Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer.

Dekker N, van Dorst E, van der Luijt R, van Gijn M, van Tuil M, Offerhaus J J Genet Couns. 2012; 22(3):345-57.

PMID: 23192360 DOI: 10.1007/s10897-012-9553-3.